INKT · MiNK Therapeutics, Inc.
$12.55
+0.29 (+2.37%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the completion of anticipated funding is not entirely within the Company's control, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 13, 2026
Market Cap
$62.15M
Shares
5.10M
Volume · Sep 30
61.14K
Avg daily vol (3M)
12.81K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.55
Open$12.62
Day$12.19–12.98
52W close$8.56–15.46
Avg vol 30d15K
Short int57K · 1.1% float · 3.1d
Short vol45%
Last earningsAug 13, 2026
DataOct 2021–Sep 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 25, 2026
Est · unconfirmed
· in 8 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$11.36M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$8.81M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+26.2%
Year over year · more shares
Price change (1Y)
-10.5%
Trailing year
Short interest
1.1%
Latest settlement · 3.1 days to cover
AI Brief
Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26
TL;DR. MiNK Therapeutics advanced agenT-797 into the randomized portion of its Phase 2 study C-1300-02 in ARDS/acute lung injury, reported initial Day 28 observations showing survival and clinical improvements, and established its first paid international named-patient access program in Brazil, while narrowing its quarterly net loss.
Bullish
- + Initiated dosing in the randomized Phase 2 trial C-1300-02 of agenT-797 in acute lung injury/ARDS under an active U.S. IND.
- + Established the company's first paid international named-patient access program in Brazil, supplying agenT-797 on a per-patient paid basis.
- + Quarterly net loss narrowed to $3.1 million ($0.62/share) from $4.2 million ($1.06/share) year over year, with six-month net loss narrowing to $5.9 million from $7.0 million.
Bearish
- − Cash and cash equivalents declined to $8.8 million as of June 30, 2026 from $13.4 million at year-end 2025.
- − Cash used in operations increased to $2.1 million in Q2 2026 from $1.6 million a year ago, reflecting deliberate Phase 2 launch costs.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
+10%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
58%
mid-range
Momentum
relative strength
1-month return
+15%
trailing
6-month return
+9%
trailing
YTD return
+13%
this year
Relative strength
−3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Accumulating
+17% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.12% of float · ▼ -12.1% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
EPS growth
−2%
Y/Y
Free cash flow
$-6.0M
Quant / Vol
risk profile
Volatility
73%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
58%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
Golden cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Accumulating
+17% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.12% of float · ▼ -12.1% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $9
Now $13 · 58%
Range high $15
vs 200-day avg +10%
vs 50-day avg +10%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INKT
this stock
MiNK Therapeutics, Inc.
|
$62.15M | +12.6% | — | — | 1.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INKT | +1.6% | +14.6% | +9.4% | +13.2% | +12.6% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +2.3% | +14.5% | -2.8% | +13.8% | +0.7% |